- Home
- AVD vs BWAY Comparison
AVD vs BWAY Comparison
Compare AVD & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- BWAY
- Stock Information
- Founded
- AVD 1969
- BWAY 2003
- Country
- AVD United States
- BWAY Israel
- Employees
- AVD N/A
- BWAY N/A
- Industry
- AVD Agricultural Chemicals
- BWAY Medical/Dental Instruments
- Sector
- AVD Industrials
- BWAY Health Care
- Exchange
- AVD Nasdaq
- BWAY Nasdaq
- Market Cap
- AVD 165.8M
- BWAY 177.4M
- IPO Year
- AVD N/A
- BWAY 2019
- Fundamental
- Price
- AVD $5.21
- BWAY $11.05
- Analyst Decision
- AVD Strong Buy
- BWAY Strong Buy
- Analyst Count
- AVD 3
- BWAY 3
- Target Price
- AVD $16.67
- BWAY $13.17
- AVG Volume (30 Days)
- AVD 357.2K
- BWAY 46.6K
- Earning Date
- AVD 03-13-2025
- BWAY 03-05-2025
- Dividend Yield
- AVD 1.16%
- BWAY N/A
- EPS Growth
- AVD N/A
- BWAY N/A
- EPS
- AVD N/A
- BWAY 0.04
- Revenue
- AVD $553,839,000.00
- BWAY $38,631,000.00
- Revenue This Year
- AVD N/A
- BWAY $388.82
- Revenue Next Year
- AVD $5.98
- BWAY $18.70
- P/E Ratio
- AVD N/A
- BWAY $128.97
- Revenue Growth
- AVD N/A
- BWAY 34.19
- 52 Week Low
- AVD $4.26
- BWAY $4.61
- 52 Week High
- AVD $14.28
- BWAY $11.08
- Technical
- Relative Strength Index (RSI)
- AVD 58.04
- BWAY 71.27
- Support Level
- AVD $4.46
- BWAY $10.08
- Resistance Level
- AVD $5.01
- BWAY $9.75
- Average True Range (ATR)
- AVD 0.24
- BWAY 0.35
- MACD
- AVD 0.10
- BWAY 0.16
- Stochastic Oscillator
- AVD 93.97
- BWAY 98.08
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.